12/06/2012

Dr. Rafael Simó, head of the diabetes and metabolism group at Vall d'Hebron Research Institute (VHIR) is the only Spanish co-author who has taken part in an international comparative study between two antidiabetic, exenatida, of new generation, and glimperidina, administered to people affected by diabetes type 2. The main results of the study, presented in the Congress of the American Diabetes Association (ADA), conclude that exenatida allows a better control of the levels of glucose, besides a decrease of the weight of the patients, and presents a minimum risk of hypoglycemias.This work, called EUREXA, has been made with the best experts from 14 countries, and has been published in the last number of The Lancet, coinciding with the ADA congress. In the study have been included diabetic patients who, in spite of the treatment, have the sugar levels badly controlled. Of all the current studies this has done a follow-up to longer term -more than 4 years- to a major number of patients.